These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

107 related items for PubMed ID: 1682042

  • 21. Optimal scheduling of interleukin 12 and chemotherapy in the murine MB-49 bladder carcinoma and B16 melanoma.
    Teicher BA, Ara G, Buxton D, Leonard J, Schaub RG.
    Clin Cancer Res; 1997 Sep; 3(9):1661-7. PubMed ID: 9815857
    [Abstract] [Full Text] [Related]

  • 22. Antitumor effects of alpha-interferon and gamma-interferon on a murine renal cancer (Renca) in vitro and in vivo.
    Sayers TJ, Wiltrout TA, McCormick K, Husted C, Wiltrout RH.
    Cancer Res; 1990 Sep 01; 50(17):5414-20. PubMed ID: 2117482
    [Abstract] [Full Text] [Related]

  • 23. Synergistic interleukin-18 and low-dose interleukin-2 promote regression of established murine neuroblastoma in vivo.
    Redlinger RE, Mailliard RB, Lotze MT, Barksdale EM.
    J Pediatr Surg; 2003 Mar 01; 38(3):301-7; discussion 301-7. PubMed ID: 12632339
    [Abstract] [Full Text] [Related]

  • 24. A convenient cancer vaccine therapy with in vivo transfer of interleukin 12 expression plasmid using gene gun technology after priming with irradiated carcinoma cells.
    Nishitani MA, Sakai T, Ishii K, Zhang M, Nakano Y, Nitta Y, Miyazaki J, Kanayama HO, Kagawa S, Himeno K.
    Cancer Gene Ther; 2002 Feb 01; 9(2):156-63. PubMed ID: 11857033
    [Abstract] [Full Text] [Related]

  • 25. Immunopharmacological and antitumor effects of second-generation immunomodulatory oligonucleotides containing synthetic CpR motifs.
    Wang D, Li Y, Yu D, Song SS, Kandimalla ER, Agrawal S.
    Int J Oncol; 2004 Apr 01; 24(4):901-8. PubMed ID: 15010828
    [Abstract] [Full Text] [Related]

  • 26. Potentiation of a dendritic cell vaccine for murine renal cell carcinoma by CpG oligonucleotides.
    Chagnon F, Tanguay S, Ozdal OL, Guan M, Ozen ZZ, Ripeau JS, Chevrette M, Elhilali MM, Thompson-Snipes LA.
    Clin Cancer Res; 2005 Feb 01; 11(3):1302-11. PubMed ID: 15709202
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Antitumor activity of a novel antitumor antibiotic, quinocarmycin citrate (KW2152).
    Fujimoto K, Oka T, Morimoto M.
    Cancer Res; 1987 Mar 15; 47(6):1516-22. PubMed ID: 2434218
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Specific targeting and killing activities of anti-P-glycoprotein monoclonal antibody MRK16 directed against intrinsically multidrug-resistant human colorectal carcinoma cell lines in the nude mouse model.
    Iwahashi T, Okochi E, Ariyoshi K, Watabe H, Amann E, Mori S, Tsuruo T, Ono K.
    Cancer Res; 1993 Nov 15; 53(22):5475-82. PubMed ID: 8106147
    [Abstract] [Full Text] [Related]

  • 31. Radio frequency ablation combined with interleukin-2 induces an antitumor immune response to renal cell carcinoma in a murine model.
    Kroeze SG, Daenen LG, Nijkamp MW, Roodhart JM, de Gast GC, Bosch JL, Jans JJ.
    J Urol; 2012 Aug 15; 188(2):607-14. PubMed ID: 22704448
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
    Kanwar JR, Kanwar RK, Pandey S, Ching LM, Krissansen GW.
    Cancer Res; 2001 Mar 01; 61(5):1948-56. PubMed ID: 11280751
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. A fluorine-containing anthracycline (ME2303) as a new antitumor agent against murine and human tumors and their multidrug-resistant sublines.
    Tsuruo T, Yusa K, Sudo Y, Takamori R, Sugimoto Y.
    Cancer Res; 1989 Oct 15; 49(20):5537-42. PubMed ID: 2790778
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Alterations in murine host defense functions by adriamycin or liposome-encapsulated adriamycin.
    Mace K, Mayhew E, Mihich E, Ehrke MJ.
    Cancer Res; 1988 Jan 01; 48(1):130-6. PubMed ID: 3257160
    [Abstract] [Full Text] [Related]

  • 38. Antitumor interaction of short-course endostatin and ionizing radiation.
    Hanna NN, Seetharam S, Mauceri HJ, Beckett MA, Jaskowiak NT, Salloum RM, Hari D, Dhanabal M, Ramchandran R, Kalluri R, Sukhatme VP, Kufe DW, Weichselbaum RR.
    Cancer J; 2000 Jan 01; 6(5):287-93. PubMed ID: 11079167
    [Abstract] [Full Text] [Related]

  • 39. Potentiation of the antitumor activity by a novel quinoline compound, MS-209, in multidrug-resistant solid tumor cell lines.
    Nakanishi O, Baba M, Saito A, Yamashita T, Sato W, Abe H, Fukazawa N, Suzuki T, Sato S, Naito M, Tsuruo T.
    Oncol Res; 1997 Jan 01; 9(2):61-9. PubMed ID: 9167187
    [Abstract] [Full Text] [Related]

  • 40. The success of locoregional, low-dose recombinant interleukin-2 therapy in tumor-bearing mice is dependent on the time of rIL-2 administration.
    Everse LA, Bernsen MR, Dullens HF, Den Otter W.
    J Exp Ther Oncol; 1996 Jul 01; 1(4):231-6. PubMed ID: 9414409
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.